1. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
- Author
-
Devin Leake, Mina J. Bissell, Elizabeth L. Godden, Derek C. Radisky, Jimmie E. Fata, Zena Werb, Hong Liu, M. Angela Nieto, Celeste M. Nelson, Laurie E. Littlepage, Dinah Levy, and Donna G. Albertson
- Subjects
rac1 GTP-Binding Protein ,rho GTP-Binding Proteins ,Genome instability ,DNA damage ,Cellular differentiation ,Mice, Transgenic ,RAC1 ,Biology ,medicine.disease_cause ,Genomic Instability ,Article ,Cell Line ,Malignant transformation ,Mesoderm ,Mice ,medicine ,Animals ,Humans ,RNA, Messenger ,Tissue homeostasis ,Multidisciplinary ,Cell Differentiation ,Epithelial Cells ,Mitochondria ,Alternative Splicing ,Cell Transformation, Neoplastic ,Biochemistry ,Cancer cell ,Cancer research ,Matrix Metalloproteinase 3 ,Reactive Oxygen Species ,Carcinogenesis ,DNA Damage - Abstract
5 páginas, 4 figuras.-- Letter., The tumour microenvironment can be a potent carcinogen, not only by facilitating cancer progression and activating dormant cancer cells, but also by stimulating tumour formation1. We have previously investigated stromelysin-1/matrix metalloproteinase-3 (MMP-3), a stromal enzyme upregulated in many breast tumours2, and found that MMP-3 can cause epithelial–mesenchymal transition (EMT) and malignant transformation in cultured cells3, 4, 5, and genomically unstable mammary carcinomas in transgenic mice3. Here we explain the molecular pathways by which MMP-3 exerts these effects: exposure of mouse mammary epithelial cells to MMP-3 induces the expression of an alternatively spliced form of Rac1, which causes an increase in cellular reactive oxygen species (ROS). The ROS stimulate the expression of the transcription factor Snail and EMT, and cause oxidative damage to DNA and genomic instability. These findings identify a previously undescribed pathway in which a component of the breast tumour microenvironment alters cellular structure in culture and tissue structure in vivo, leading to malignant transformation., This work was supported by grants from the OBER office of the Department of Energy and an Innovator award from the Department of Defense (to M.J.B.) and from the National Institutes of Health (to M.J.B. and Z.W.), and by fellowships from the American Cancer Society (D.C.R.), the National Cancer Institute (L.E.L.), the Department of Defense (H.L. and C.M.N.) and the California Breast Cancer Research Program (J.E.F).
- Published
- 2005
- Full Text
- View/download PDF